Characterization of a novel bacteriophage endolysin (LysAB1245) with extended lytic activity against distinct capsular types associated with Acinetobacter baumannii resistance

Rosesathorn Soontarach,Potjanee Srimanote,Buppa Arechanajan,Alisa Nakkaew,Supayang Piyawan Voravuthikunchai,Sarunyou Chusri
DOI: https://doi.org/10.1371/journal.pone.0296453
IF: 3.7
2024-01-02
PLoS ONE
Abstract:Capsular polysaccharides are considered as major virulence factors associated with the ability of multidrug-resistant (MDR) Acinetobacter baumannii to cause severe infections. In this study, LysAB1245, a novel bacteriophage-encoded endolysin consisting of a lysozyme-like domain from phage T1245 was successfully expressed, purified, and evaluated for its antibacterial activity against distinct capsular types associated with A . baumannii resistance. The results revealed a broad spectrum activity of LysAB1245 against all clinical MDR A . baumannii isolates belonging to capsular type (KL) 2, 3, 6, 10, 47, 49, and 52 and A . baumannii ATCC 19606. At 2 h following the treatment with 1.7 unit/reaction of LysAB1245, more than 3 log reduction in the numbers of bacterial survival was observed. In addition, LysAB1245 displayed rapid bactericidal activity within 30 min (nearly 3 log CFU/mL of bacterial reduction). Thermostability assay indicated that LysAB1245 was stable over a broad range of temperature from 4 to 70°C, while pH sensitivity assay demonstrated a wide range of pH from 4.5 to 10.5. Furthermore, both minimal inhibitory concentration (MIC) and minimal bactericidal concentration (MBC) of LysAB1245 against all MDR A . baumannii isolates and A . baumannii ATCC 19606 were 4.21 μg/mL (0.1 unit/reaction). Conclusively, these results suggest that LysAB1245 possesses potential application for the treatment of nosocomial MDR A . baumannii infections.
multidisciplinary sciences
What problem does this paper attempt to address?